Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5302
Revised: July 10, 2013
Accepted: July 17, 2013
Published online: August 28, 2013
Processing time: 102 Days and 23.8 Hours
AIM: To assess the clinical significance and the prognostic value of preoperative serum carbohydrate antigen 19-9 (CA 19-9) level in gastric cancer.
METHODS: Between January 2005 and December 2006, 1960 patients underwent surgery for histologically confirmed gastric cancer. Of these, 163 patients had elevated serum levels of CA 19-9 preoperatively, and 1628 patients had normal serum levels of CA 19-9 preoperatively. For this study, 325 patients were selected from the group of 1628 patients by age, sex, and cancer stage to serve as controls. Statistically significant differences in survival rates were calculated using the log-rank test. A P value less than 0.05 was considered statistically significant and was determined using SAS software.
RESULTS: The baseline characteristics showed some differences between the two groups with regard to histology. Overall survival (OS) in the elevated and non-elevated group was 37.90 and 68.67 mo, respectively (P < 0.001). N stage (P = 0.001) was a significant predictor of disease-free survival by multivariate analysis. Also, N stage (P < 0.001), and the presence of peritoneal metastasis (P < 0.001) remained independent factors in predicting OS by multivariate analysis. Additionally, preoperative serum CA 19-9 levels were significantly associated with OS in univariate (P = 0.009) and multivariate (P = 0.021) analyses.
CONCLUSION: Serum CA 19-9 can be considered an independent prognostic factor in predicting OS in patients anticipating surgery for gastric cancer.
Core tip: The exact functions of preoperative carbohydrate antigen (CA) 19-9 in stomach cancer have yet to be uncovered. We sought to assess the clinical significance of preoperatively high levels of CA 19-9 in patients with gastric cancer and aimed to investigate the relationship between serum levels of CA 19-9 and disease-free survival and overall survival (OS). We conclude that OS in gastric cancer patients with elevated CA 19-9 levels was lower than that in patients with non-elevated levels. Serum CA 19-9 can be considered an independent prognostic factor in predicting OS in patients anticipating surgery for gastric cancer.